Clinical trial
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT00358930 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry · Completed
Key facts
| NCT number | NCT00358930 |
|---|---|
| Title | A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck |
| Official title | A Phase 2 Study of ARQ 501 in Patients With Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Neoplasms, Carcinoma, Squamous Cell |
| Intervention type | Drug |
| Interventions | ARQ 501 |
| Enrollment | 60 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Aug 1, 2006 |
| Last update posted | Apr 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: